Prefilled Syringe Patents: Who Leads, Where the Gaps Are 2026
- Filing has cooled since a 2019 peak of 53. with the 2022 midpoint at 26 and later years falling toward single digits — this is a maturing claim space, not a growing one.
- One 1990s-era stopper patent still anchors the field. US6090081A on syringe sealing stoppers carries 285 citations, far ahead of any later filing, meaning core sealing geometry was staked out early.
- No assignee shows growth in the latest tracked year. every named assignee in the momentum data sits at zero or a full year-on-year drop, consistent with a corpus of expired priority pushes rather than fresh entrants.
Filing growth compares 2021 (27 records) with 2024 (16) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 495 records in scope (CR5), not by the ranked leaders only.
A narrow, IPC-concentrated field built around glass, silicone and closure mechanics
Prefilled syringe and container closure patenting sits almost entirely inside a single IPC subclass: A61M (devices for body fluids) appears in 494 of 495 records, meaning the field is defined by device mechanics — barrel, stopper, needle shield, tip cap — rather than by the drug formulation inside. Secondary clusters in A61K medicinal preparations and A61L sterilising and disinfecting show where formulation and sterility claims overlap the hardware, and a smaller A61J and C08L presence points to polymer stopper and container material claims running alongside the mechanical core.
The filing trend has been flat-to-declining since 2019, and because publication typically lags filing by around 18 months, the most recent one or two years in any chart will understate real activity. Even allowing for that lag, the shape of the curve — a clear peak followed by a steady fall to a 2026 count of 1 — points to a technology where the foundational claims are already filed and later work is incremental.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
495 patent families published between 2015 and mid-2026, drawn from a search string that pairs prefilled syringe and container closure terminology with silicone oil, break-loose force, glass delamination, extractables and needle shield concepts across three IPC classes.
A 2019 peak followed by a sustained decline
Filings rose to 53 in 2019 from 42 in 2017, then eased through a 2022 midpoint of 26 down toward a single filing in the partial 2026 year. Read the tail end cautiously: publication lag means 2025-2026 filings are still arriving.
A61M dominates; formulation and sterility classes trail
A61M appears in 494 of 495 records, confirming this is fundamentally a device-mechanics corpus. A61K (94), A61L (42) and A61J (32) show where drug-contact and sterility claims intersect the hardware, while C08L, A61P, C07K and C01B mark smaller pockets of polymer, therapeutic-activity, peptide and inorganic-material claiming.
Shares are the percentage of the 495 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Prefilled Syringes and Container Closure with Eureka
This page is one run against one query. Ask Eureka your own question about prefilled syringes and container closure and every answer comes back with the patent numbers behind it.
Try EurekaThe citation anchors and a representative recent filing
US11331434B2 — Botulinum toxin prefilled syringe system (Merz Pharma, 2022-05-17)
The present invention relates a botulinum toxin prefilled syringe system with desirable injection force characteristics, in particular low gliding force and low break loose force, comprising a syringe barrel of glass containing a liquid botulinum toxin composition, a plunger stopper and a closure device such as a tip cap or a needle shield. In addition, the present invention relates to a kit comprising the botulinum toxin prefilled syringe system, and optionally instructions for use, and to the use of the botulinum toxin prefilled syringe system in therapeutic and cosmetic applications.Ties a specific drug (botulinum toxin) to specific force parameters (gliding force, break-loose force) and specific closure hardware — a claim style that narrows scope to a drug-device combination rather than the hardware alone.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6090081A | Sealing stopper for a syringe and a prefilled syringe | 285 |
| 2 | US20130060231A1 | Auto-injector for retractable prefilled syringe | 168 |
| 3 | US20050075611A1 | Low extractable, thermoplastic syringe and tip cap | 156 |
| 4 | US20140194854A1 | Subcutaneous and intradermal patch infusers | 146 |
| 5 | US5899889A | Prefilled syringe | 138 |
| 6 | EP0879611A2 | A sealing stopper for a syringe and a prefilled syringe | 104 |
| 7 | WO2005032627A1 | Low extractable, thermoplastic syringe and tip cap | 85 |
| 8 | US6142976A | Prefilled syringe | 82 |
| 9 | US6142977A | Prefilled, sterilized syringe with a new and improved plug | 82 |
| 10 | US20170182242A1 | Wearable Automatic Injection Device and Related Methods of Use | 79 |
Citation counts inside a searched corpus favour older filings simply because they have had longer to accumulate citations — treat this table as a map of influence, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once the raw counts are put in context: where the earliest claims sit, how citation is distributed, and how thin cross-assignee collaboration is.
The growth phase has already happened
The corpus peaked in 2019 and has declined every year since, with the 2022 midpoint at 26. New entrants filing broad mechanical claims on barrel, stopper or needle-shield geometry now compete against a decade of prior art rather than an open field.
Core sealing geometry was claimed early and cited heavily
US6090081A on syringe sealing stoppers leads the citation table by a wide margin over the next-ranked records, which cluster in the 130-170 range. That gap signals the foundational stopper-sealing concept is well settled law, not open ground.
Cross-assignee collaboration is rare and one pairing dominates it
Only ten co-assignee pairs appear across the whole dataset, and the strongest pairing accounts for the bulk of that collaborative activity while the next pairings drop to single-digit counts. Most filing in this field is done by a single assignee alone.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to prefilled syringes and container closure, with the prior art for and against each one.
Who is filing, and where the momentum has stalled
The assignee list is dense with device and pharma names, but the momentum data tells a consistent story: nobody tracked shows growth in the most recent year.
No assignee is currently accelerating
Every named assignee in the recent-year momentum data — from device makers to pharma filers — shows zero filings in the latest tracked year, several with a full year-on-year drop from a prior filing. This is consistent with a field past its filing peak rather than one attracting new investment.
Filing is concentrated in the US and Europe, with a meaningful India presence
The United States and the European Patent Office receive the largest share of filings, with Israel, WIPO/PCT, India and Australia forming a second tier. A 37-filing India count is notable for a device-mechanics field and worth checking for freedom-to-operate before manufacturing there.
One collaboration stands well above the rest
The strongest co-assignee pairing in the dataset accounts for ten joint filings, notably ahead of the next pairings which sit at four and two. That concentration suggests a specific long-running technical partnership rather than a broad industry pattern of co-filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Terumo Corporation | 0 | — |
| Kaleo, Inc. | 0 | -100% |
| Becton, Dickinson and Company | 0 | -100% |
| Menzfarma S.A. | 0 | -100% |
| Kortuc Inc. | 0 | — |
| Teva Pharmaceuticals International GmbH | 0 | — |
| Cilag GmbH International | 0 | — |
| F. Hoffmann-La Roche AG | 0 | -100% |
Where to take this analysis
The dataset points to a settled core and a thinning filing rate — the next steps depend on whether you are clearing a design or planning a filing.
Run a freedom-to-operate check against the citation anchors
Before finalising a stopper, tip cap or needle-shield design, check it against the small set of heavily-cited foundational patents rather than the full 495-record set, since those anchor claims are where blocking risk concentrates.
Explore prior art with Patsnap EurekaMap the India and PCT filings for regional strategy
With India at 37 filings and WIPO/PCT at 38, a regional manufacturing or licensing plan should treat these as a distinct filing pattern from the US/EPO core rather than an afterthought.
Build a jurisdiction view in Patsnap EurekaWatch for revival in the under-claimed branches
Glass delamination mitigation and low-extractable elastomer formulations show thinner density than the core mechanical claims; a new filing surge in either would be an early signal worth tracking.
Set up alerts in Patsnap EurekaCommon questions on prefilled syringe and container closure patents
The single most-cited record in this corpus is US6090081A, a syringe sealing stopper patent with 285 citations, well ahead of the next tier of records which sit between roughly 138 and 168 citations. High citation counts favour older patents simply because they have had more time to accumulate references, so this reflects long-standing influence over stopper-sealing design rather than current commercial dominance. Anyone drafting new stopper or seal claims should review this record and its citing family closely, since it appears to anchor a large share of downstream design decisions.
No — filings peaked at 53 in 2019, sat at a midpoint of 26 in 2022, and have declined toward a single filing in the partial 2026 year. Publication lag of roughly 18 months means the last one to two years are understated in any raw count, but even accounting for that the multi-year decline from the 2019 peak is a real trend, not a data artefact. This pattern is more typical of a technology where foundational mechanical claims are largely filed and later activity is incremental improvement.
Relative to the dense core claims around barrel, stopper and needle-shield mechanics, branches such as silicone-free stopper coatings, glass delamination mitigation and low-extractable elastomer formulations show thinner filing density in this dataset. These areas sit at the intersection of materials science and device mechanics, which may explain why fewer assignees have filed comprehensive claim sets there. A first claim in one of these branches would typically need to tie a specific material or coating chemistry to a measurable performance parameter, such as extractable-compound threshold or delamination resistance under defined storage conditions, to stand apart from the broader mechanical prior art.
The United States leads with 132 filings, followed by the European Patent Office at 113, then a second tier including Israel at 44, WIPO/PCT at 38, India at 37 and Australia at 32. This distribution suggests companies are prioritising US and European protection first, with India and PCT routes used for broader geographic coverage. Anyone planning manufacturing or distribution in India specifically should note the 37-filing count there is not negligible for a device-mechanics field and warrants its own freedom-to-operate review.
US11331434B2, held by Merz Pharma, claims a botulinum toxin prefilled syringe system defined by specific injection force characteristics — low gliding force and low break-loose force — combined with a glass barrel, plunger stopper and a closure device such as a tip cap or needle shield. Because the claim ties those force parameters to a specific drug product, it is narrower than a general syringe-hardware patent and primarily constrains botulinum toxin prefilled syringe products rather than prefilled syringes generally. Designs using different drug products, different force profiles, or closure hardware outside the claimed configuration have room to operate, but any botulinum toxin syringe program should review this claim set specifically before finalising a design.
Research Prefilled Syringes and Container Closure in depth with Eureka
Go past this page: query the whole prefilled syringes and container closure corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.